X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Elecsys pTau181

    FDA Clears Elecsys pTau181 Alzheimer’s Test by Roche, Lilly

    Aligned Pathway

    UK Grants Pharma Firms Early Access to Aligned Pathway

    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Elecsys pTau181

    FDA Clears Elecsys pTau181 Alzheimer’s Test by Roche, Lilly

    Aligned Pathway

    UK Grants Pharma Firms Early Access to Aligned Pathway

    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

FDA approves Jardiance tablets for type 2 diabetes

Yuvraj_pawp by Yuvraj_pawp
4th August 2014
in Americas, FDA Approvals, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) tablets, developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an addition to diet and exercise to improve glycemic control in adults with type II diabetes.

Jardiance is a once-daily, 10mg or 25mg tablet that was approved in the US based on data from a large clinical programme comprising at least ten multinational clinical trials and more than 13,000 adults with type II diabetes.

In Phase III clinical trials, patients demonstrated a significant reduction in hemoglobin A1C and fasting blood sugar after 24 weeks, using Jardiance as a standalone treatment or in combination with a range of background treatments, including metformin, sulfonylureas, insulin and pioglitazone.

Urinary tract infections and vaginal yeast infections were the most common adverse reactions associated with Jardiance in these studies.

Hypoglycemia was more commonly reported in patients treated with the combination of Jardiance and sulfonylurea or insulin.

“Jardiance is a new option that has been shown in clinical trials to reduce blood sugar levels.”

Boehringer metabolic-clinical development and medical affairs vice-president Dr Christophe Arbet-Engels said: “Jardiance is a new option that has been shown in clinical trials to reduce blood sugar levels.

“Although not approved for weight loss, modest weight loss was also observed in these clinical trials.”

Empagliflozin is a sodium glucose co-transporter 2 inhibitor that blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

Jardiance is not for people with type I diabetes or for people with diabetic ketoacidosis.

In January 2011, Boehringer Ingelheim and Lilly announced their alliance to develop compounds for several of the largest diabetes treatment classes. Jardiance is the third diabetes medicine they have developed as part of this alliance.

 

Tags: America
Previous Post

Rosetta Genomics Announces Agreement With Global Pharmaceutical Company to Advance Efforts in Alzheimer's Disease Diagnostics

Next Post

Pharma firms earn high margins; govt asked to cut MRP of drugs

Related Posts

Elecsys pTau181
Americas

FDA Clears Elecsys pTau181 Alzheimer’s Test by Roche, Lilly

16th October 2025
mRNA Vaccine Facility
Africa

EIB, EC to Finance BioNTech’s Kigali mRNA Vaccine Facility

15th October 2025
Aligned Pathway
Drug Development

UK Grants Pharma Firms Early Access to Aligned Pathway

14th October 2025
idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
Next Post

Alexion receives orphan drug designation for Soliris in Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In